Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q1 2024 Earnings Conference
Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q1 2024 Earnings Conference
The following is a summary of the Knight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call Transcript:
以下是奈特療法公司（KHTRF）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Knight Therapeutics reported Q1 2024 revenues of over $85 million, a growth of $3 million or 4% over the same period in the previous year.
The company's infectious disease portfolio contributed to $38 million of revenues, a rise of 23% compared to Q1 2023.
Gross margin was reported at $40.7 million or 47% of revenues.
They recorded a net loss of approximately $16 million, driven by unrealized losses on the valuation of certain private investments.
Cash flows from operations were $30.8 million.
Knight Therapeutics報告稱，2024年第一季度收入超過8500萬美元，比去年同期增長300萬美元，增長4％。
該公司的傳染病投資組合帶來了3,800萬美元的收入，與2023年第一季度相比增長了23％。
據報道，毛利率爲4,070萬美元，佔收入的47％。
由於某些私人投資估值的未實現虧損，他們錄得約1,600萬美元的淨虧損。
運營現金流爲3,080萬美元。
Business Progress:
業務進展：
Knight launched three products and advanced their pipeline with regulatory submission for fostamatinib in Brazil and the approval of Karfib in Colombia.
By the end of Q1 2024, the company had nine products under regulatory review in various countries.
The company added two products, IPX203 and JORNAY PM, for Canada and Latin America within the year.
Knight has entered into an exclusive supply and distribution agreement for JORNAY PM for Canada and Latin America.
They continue to execute on their strategy of leveraging their unique platform to in-license and acquire innovative products for Canada and Latin America.
Knight推出了三款產品，並通過巴西的fostamatinib監管申請和哥倫比亞Karfib的批准來推進其產品線。
到2024年第一季度末，該公司有九種產品在不同國家接受監管審查。
該公司在年內爲加拿大和拉丁美洲增加了兩款產品，即 IPX203 和 JORNAY PM。
Knight已爲加拿大和拉丁美洲的JORNAY PM簽訂了獨家供應和分銷協議。
他們繼續執行利用其獨特平台爲加拿大和拉丁美洲許可和收購創新產品的戰略。
More details: KNIGHT THERAPEUTICS INC IR
更多詳情： 騎士療法公司IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。